目的:比较ⅢC期宫颈癌采用淋巴结清扫术和延伸野根治性放疗的近期疗效和副作用.方法:回顾性分析我院2017年1月至2020年10月收治的ⅢC期宫颈癌患者56例,26例行腹主动脉旁淋巴结清扫术+宫颈病灶根治性放射治疗;30例直接采用延伸野根治性放射治疗,分析比较两组的近期疗效,放射性并发症.结果:采用淋巴结清扫术组的患者近期疗效较好,对比延伸野放疗组差异有统计学意义(P<0.05).放射性肠炎的发生率也明显低于延伸野放疗组(P<0.05).放射性膀胱炎、骨髓抑制和延伸野放疗比较,差异无统计学意义(P>0.05).结论:对于ⅢC期宫颈癌患者,采用淋巴结清扫联合宫颈病灶根治性放射治疗近期临床疗效好,并发症少.

目的 探讨采用3D打印技术制作的阴道多通道个体化模型塞插植治疗宫颈癌的近期疗效.方法 2013年11月至2015年8月收治的30例宫颈癌患者接受常规腔内治疗(ICBT),作为ICBT组,2015年9月至2016年10月收治的26例宫颈癌患者接受3D打印插植治疗(3DP-ISBT),作为3DP-ISBT组.比较两组患者的剂量学结果[高危临床靶体积(HR-CTV)D90和膀胱、直肠、乙状结肠D2cc],并评价近期疗效.结果 肿瘤直径5～6 cm、肿瘤直径≥7 cm、阴道侵犯﹥2/3及有宫旁侵犯的3DP-ISBT组宫颈癌患者HR-CTV D90均明显高于ICBT组患者,差异均有统计学意义(P﹤0.01).3DP-ISBT组患者直肠、乙状结肠的D2cc均低于ICBT组,差异均有统计学意义(P﹤0.05).3DP-ISBT组患者1年肿瘤局部控制率为86.2％,高于ICBT组的58.3％,差异有统计学意义(P﹤0.05).治疗期间无严重不良反应.结论 与传统腔内治疗相比,3D打印多通道个体化阴道模型塞插植治疗宫颈癌具有更好的剂量学优势,且近期疗效较好,但长期疗效及不良反应还需要进一步评估.

Radiotherapy resistance is one of the key factors of poor prognosis of ovarian cancer clinical treatment. The search for key targets of ovarian cancer radiotherapy resistance has become a high priority. Long noncoding RNA plays an important role in tumor development. However, the key lncRNA in ovarian cancer radiotherapy resistance is not identified. Our finding that lncRNA CRNDE is highly expressed in the radiotherapy resistance cell line CAOV3/R drew our attention. Therefore, in this study, we targeted lncRNA CRNDE to analyze whether it is a key factor of radiotherapy resistance in ovarian cancer. Ultimately, we found that silencing lncRNA CRNDE could reverse CAOV3/R radiotherapy resistance, which would be a boon to clinical treatment.

BACKGROUND:In recent years, the incidence of cervical cancer has increased with increasing life pressures and changes in women's social roles, posing a serious threat to women's physical and mental health. AIM:To explore the clinical effect of Endo combined with concurrent radiotherapy and chemotherapy in the treatment of advanced cervical squamous cell carcinoma. METHODS:A total of 120 patients admitted to the oncology department of our hospital were selected as the research subjects. They were equally divided into the test group and the control group (60 patients each) with a random number table. The test group was treated with Endo combined with concurrent radiotherapy and chemotherapy, and the control group was treated with concurrent radiotherapy and chemotherapy. We compared the serum thymidine kinase 1 (TK1), human epididymis protein 4 (HE4), vascular endothelial growth factor (VEGF), and squamous cell carcinoma-associated antigen (SCC-Ag) levels, the clinical effects and survival before and after radiotherapy and chemotherapy, the quality score, and the 3-year follow-up outcomes between the two groups. RESULTS:After chemotherapy, the complete remission + partial remission rate was 85.00% in the test group and 68.33% in the control group; the difference was not statistically significant (P > 0.05). Before chemotherapy, the serum TK1, HE4, VEGF, and SCC-Ag levels of the two groups were not significantly different (P > 0.05). After chemotherapy, the levels of serum TK1 (1.27 ± 0.40 pmol/L), HE4 (81.4 ± 24.0 pmol/L), VEGF (235.1 ± 38.0 pg/mL), and SCC-Ag (1.76 ± 0.55 ng/mL) were lower than those in the control group [TK1 (1.58 ± 0.51 pmol/L), HE4 (98.0 ± 28.6) pmol/L, VEGF (284.2 ± 54.1 pg/mL), and SCC-Ag (2.34 ± 0.78 ng/mL)]. The difference was statistically significant (P < 0.05). Before chemotherapy, there were no significant differences in the physical, role, mood, cognition, social and symptom scale scores of the two groups (P > 0.05). After chemotherapy, the physical, role, mood, cognitive and social scores were higher in the test group than in the control group, and the difference was statistically significant (P < 0.05). The symptom scale scores of the test group were all lower than those of the control group, and the difference was statistically significant (P < 0.05). The 3-year progression-free survival (PFS) rate was 43.33% in the test group and 26.67% in the control group; the overall survival (OS) rate was 48.33% in the test group and 33.33% in the control group; the differences were not statistically significant (P > 0.05). The 3-year PFS time of the test group was 20.0 mo, which was longer than that of the control group (15.0 mo), and the difference was significant (P < 0.05). The OS time of the test group was 30.0 mo, which was longer than that of the control group (18.0 mo), and the difference was significant (P < 0.05). CONCLUSION:Endo combined with concurrent radiotherapy and chemotherapy for the treatment of advanced cervical squamous cell carcinoma has a positive effect on reducing the level of tumor markers in patients, prolonging the PFS and OS times of patients, and improving the quality of life.

目的 比较分析Ⅱb～Ⅲb期宫颈癌腔内联合宫旁插植近距离治疗计划中的3种优化方法的剂量学差异.方法 选取Ⅱb～Ⅲb期宫颈癌患者33例,对每例患者制订3种计划,分别为手动优化组、模拟退火逆向计划优化算法(IPSA)组、混合逆向计划优化算法(HIPO)组.比较3组计划中高危临床靶区(HR-CTV)的体积剂量参数V150、V100、D100、D90、均匀性指数(HI),以及危及器官(直肠、膀胱、乙状结肠)的剂量参数D0.1 cm3、D1 cm3、D2 cm3.结果 IPSA组和HIPO组的V150、V100均低于手动优化组,HI均高于手动优化组,HIPO组的V100高于IPSA组,差异均有统计学意义(P﹤0.05).IPSA组和HIPO组直肠、膀胱、乙状结肠的D0.1 cm3、D1 cm3和D2 cm3均低于手动计划组,差异均有统计学意义(P﹤0.05);HIPO组直肠、膀胱的D0.1 cm3、D1 cm3和D2 cm3均低于IPSA组,差异均有统计学意义(P﹤0.05).结论 对于局部晚期宫颈癌腔内联合宫旁插植技术,基于3组优化方法的计划均能满足临床需求.HIPO计划和IPSA计划能提高靶区剂量覆盖;HIPO计划较IPSA计划可以进一步提高靶区的V100和HI指数,同时减少膀胱和直肠的受量.

目的:探讨注射聚乙二醇重组人粒细胞集落刺激因子(PEG-rhG-CSF)治疗宫颈癌化疗所致中性粒细胞减少症的有效性和安全性.方法:筛选2016年1月-2018年12月来甘肃省肿瘤医院进行宫颈癌治疗的女性患者162例,随机分成对照组和治疗组.对照组79例,平均年龄为(38.7±3.6)岁;治疗组83例,平均年龄为(41.2±4.3岁).2组皆进行同步放化疗,对照组患者化疗24 h注射重组人粒细胞集落刺激因子(rhG-CSF),治疗组患者化疗24 h后注射聚乙二醇重组人粒细胞集落刺激因子(PEG-rhG-CSF);2组患者化疗后定期复查血常规,检查骨髓抑制差异、中性粒细胞绝对值随时间变化差异、化疗延迟率及不良反应发生率.结果:治疗组给药后12～144 h中性粒细胞数与增殖率,化疗第一周期中性粒细胞数减少、白细胞减少方面均有显著差异(P＜0.05);治疗组中性粒细胞数绝对值在不同时间点高于对照组,在给药第5、10天有显著性差异(P＜0.05);另外治疗组的化疗延迟人数少于对照组(P＜0.05);2组不良反应无显著差异(P＞0.05).结论:PEG-rhG-CSF在治疗宫颈癌同步放化疗中有较好的疗效和安全性.

目的 探讨腔内联合宫旁插植治疗(IC/ISBT)和腔内后装治疗(ICBT)对局部晚期宫颈癌的临床疗效.方法 选取经体外照射放疗(50 Gy/25 f)后肿瘤消退不明显且宫旁受侵的局部晚期(ⅡB～ⅢB期)宫颈癌患者100例.采用随机数字表法将患者分为ICBT组和IC/ISBT组,每组50例.然后进行CT,将图像传至Oncentra Brachy Therapy计划系统,行靶区勾画,采用模拟退火逆向优化方式进行计划设计,比较ICBT组和IC/ISBT组患者的近期疗效、肿瘤复发或转移率、并发症发生率.结果 IC/ISBT组患者的完全缓解(CR)率为96.0％,高于ICBT组的88.0％,差异有统计学意义(P﹤0.05);IC/ISBT组患者的客观缓解率(ORR)为98.0％,高于ICBT组的92.0％,差异有统计学意义(P﹤0.05).IC/ISBT组患者的肿瘤复发或转移率为4.0％,低于ICBT组的16.0％,差异有统计学意义(P﹤0.05).IC/ISBT组患者放射性皮炎的发生率为38.0％,与ICBT组的42.0％比较,差异无统计学意义(P﹥0.05);IC/ISBT组患者放射性直肠炎的发生率为14.0％,低于ICBT组的32.0％,差异有统计学意义(P﹤0.05);IC/ISBT组患者放射性膀胱炎的发生率为30.0％,与ICBT组的28.0％比较,差异无统计学意义(P﹥0.05).结论 对外照射后肿瘤消退不明显、宫旁受侵的局部晚期宫颈癌患者采用IC/ISBT治疗方式,可取得较好的宫旁控制率和近期疗效,且能够降低放射性直肠炎的发生率,值得临床推广应用.

为提高硅胶填充物(Bolus)使用的可靠性,对比4种不同厚度Bolus设置方式产生的空腔大小对乳腺癌根治术后调强放疗的剂量学影响.根据空腔大小范围制定3套适形调强放射治疗(Intensity-modulated radiation therapy,IMRT)计划方案Plan1(空腔大于10 mm)、Plan2(空腔大于5 mm且小于10 mm)、Plan3(空腔小于2 mm),并与常规计划设计下Bolus服帖在皮肤上无空腔的IMRT(Plan4)进行剂量对比,分析剂量–体积直方图(DVH)与三维剂量分布图,采用统计软件包(SPSS)对数据进行统计分析,评价靶区和危及器官的剂量分布差异.统计分析得知,4种方案所有靶区剂量学指标均满足处方剂量要求,且无统计学差异(p>0.05);但剂量分布图显示,Plan1与Plan2空腔附近靶区聚集不等范围的高剂量区及近皮肤剂量不足区,Plan1程度较Plan2大;DVH结果显示,Plan3与Plan4能够更好降低食管平均剂量Dmean、气管平均剂量Dmean、患侧肺接受≥30 Gy照射的体积百分比V30,以及辅助结构Ring接受≥40 Gy、45 Gy照射体积百分比V40、V45,且差异均有统计学差异(p<0.05).对比得知,小空腔(小于2 mm)能够减少靶区内的冷点与热点,降低危及器官受量,更接近理想计划方案.Plan3采用2 mm叠加3 mm的方式,将大空腔缩小至2 mm以下,既能满足Bolus的补偿作用,又能避免Bolus物理特性引起的剂量学误差,保证治疗质量.

目的 分析宫颈癌术后阴道残端复发调强放射治疗联合插植近距离后装治疗的疗效及毒副反应.方法 选择2013年1月至2014年12月收治的宫颈癌术后阴道断端复发患者65例,随机分为2组.ISBT组(37例)行调强放射治疗联合插植近距离后装治疗,ICBT组(28例)行调强放射治疗联合常规近距离后装治疗,2组放疗期间均给予顺铂周疗增敏治疗.比较2组的疗效差异和毒副反应.结果 随访时间为12～45个月,随访率100％.ISBT组完全有效率CR+部分有效率PR 89.2％(33/37),ICBT组完全有效率CR+部分有效率PR 64.3％(18/28).2组CR+PR比较差异有统计学意义(χ2=5.306,P=0.021).1、2、3年局控率,ISBT组分别为83.7％、72.9％、43.2％,ICBT组分别为75.7％、57.1％、10.7％,差异有统计学意义(χ2=5.323,P=0.019).1、2、3年生存率,ISBT组分别为86.5％、75.6％、43.2％,ICBT组分别为78.5％、60.7％、21.4％,差异有统计学意义(χ2=4.758,P=0.029).毒副反应:放射性膀胱炎发生率2组分别为10.8％、32.1％,2组比较差异有统计学意义(χ2=4.533,P=0.033);放射性直肠炎发生率2组分别为13.5％、39.3％,差异有统计学意义(χ2=5.795,P=0.012).结论 宫颈癌术后阴道断端复发调强放射治疗联合插植近距离后装治疗与体外三维适形放疗联合传统腔内放射治疗相比有明显优势,具有疗效好、毒副反应轻的特点,患者耐受性好.

目的 比较3D腔镜、2D腔镜和开放手术治疗甲状腺癌的效果,并探讨其对患者炎症应激反应的影响.方法 选择2017年5月至2019年5月于西安国际医学中心医院就诊的甲状腺癌患者96例,按随机数表法分为3D腔镜组、2D腔镜组和开放手术组各32例,分别行3D腔镜手术、2D腔镜手术和开放手术.三组患者术后均随访3个月.比较三组患者的围术期相关指标、淋巴结清扫数、淋巴结阳性数、对切口美容满意度和不良反应发生率,同时比较三组患者手术前、手术后1 d的血清白细胞介素-6(IL-6)、C反应蛋白(CRP)及白细胞(WBC)水平.结果 3D腔镜组患者术中出血量、住院时间分别为(41.33±4.13)mL、(5.25±0.53)d,明显少于2D腔镜组的(61.57±6.16)mL、(5.64±0.56)d及开放手术组的(89.02±8.90)mL、(6.03±0.60)d,差异均有统计学意义(P<0.05);2D腔镜组患者的手术时间为(146.48±14.65)min,明显长于3D腔镜组的(120.35±12.04)min和开放手术(100.17±10.02)min,差异均有统计学意义(P<0.05);2D腔镜组患者的引流量为(170.21±17.02)mL,明显多于3D腔镜组的(131.48±13.15)mL及开放手术组的(108.94±10.89)mL,差异均有统计学意义(P<0.05);三组患者的淋巴结清扫数及淋巴结阳性数比较差异均无统计学意义(P>0.05);开放手术组患者术后1 d的IL-6、CRP、WBC水平分别为(3.13±0.31)pg/mL、(4.79±0.48)g/mL、(10.17±1.02)×109/L,明显高于3D腔镜组的(2.65±0.27)pg/mL、(3.44±0.34)g/mL、(9.33±0.93)×109/L及2D腔镜组的(2.77±0.28)pg/mL、(3.55±0.36)g/mL、(9.54±0.95)×109/L,差异均有统计学意义(P<0.05),但3D腔镜组和2D腔镜组患者的IL-6、CRP、WBC比较差异均无统计学意义(P>0.05);3D腔镜组和2D腔镜组患者的切口美容满意度分别为84.38％、81.25％,明显高于开放手术组的56.25％,差异有统计学意义(P<0.05);三组患者术后不良反应发生率比较差异无统计学意义(P>0.05).结论 3D腔镜、2D腔镜和开放手术治疗甲状腺癌疗效无明显差异,腔镜手术引起炎症应激反应显著低于开放手术,3D腔镜组术中出血量和住院时间更短,但手术时间长于2D腔镜组,临床可根据患者实际情况进行选择.

ObjectiveTo evaluate the reported quality of randomized controlled trials (RCTs) literature abstract of endometrial cancer published in Chinese using the abstract CONSORT statement.MethodsEndometrial-cancer-related RCTs were searched in CNKI, CBM, VIP and WF databases from inception to March 2017. the literature abstracts were conducted quality assessment in accordance with the abstract CONSORT standard. Meta-Analyst and RevMan5.1 software were used for statistical analysis.ResultsA total of 171 Chinese RCTs were included which the published areas were mainly Sichuan, Heilongjiang, Guangdong, Henan and Shandong. The number of reference writers ranged from 1 to 3, with a total of 131 articles (76.6%). Statistical data showed that the number of published articles has increased significantly and reached to 164 (95.9%) since the publication of the abstract CONSORT in 2008. The quality of the 11 entries in the RCTs has been significantly improved. In addition, the complete reporting rate of 5 articles (2.9%) collected by CSCD was significantly higher than that of the 164 non-CSCD articles (95.9%).The serious reporting flaws were appeared for RCT abstract of endometrial cancer regarding following items: title randomized, subject, investigated outcome indes, randomization, blinding, statistical methods, numbers analysised, trial registration, funding. The pooled RR with 95%CI were 0.3(0, 4.5), 7.0(4.0, 11.9), 0.3(0, 4.5), 12.3(8.1, 18.1), 1.2(0.3, 4.6), 5.8(3.2, 10.5), 4.1(2.0, 8.3), 0.3(0, 4.5), 10.5(6.7, 16.1), respectivly．ConclusionAt present, Chinese published endometrial cancer RCT abstract quality is poor. In this study, the quality of these RCT reports are evaluated by CONSORT in order to understand the current status and to improve the quality of Chinese abstracts published for endometrial cancer RCTs.

目的 检测子宫颈鳞状上皮内病变(squamous intraepithelial lesion,SIL)组织中BAG-1、MCM2及p16蛋白的表达,探讨其与SIL进展程度、p16表达及高危型人乳头瘤病毒(high-risk human papillomavirus,HR-HPV)感染的相关性.方法 采用免疫组化EnVision两步法检测36例正常子宫颈/慢性子宫颈炎、77例低度鳞状上皮内病变(low-grade squamous intraepithelial le-sion,LSIL)、69例高度鳞状上皮内病变(high-grade squamous intraepithelial lesion,HSIL)组织中BAG-1、MCM2及p16蛋白的表达,并用PCR反向点杂交法对所有样本行HPV基因分型检测.结果 BAG-1、MCM2及p16蛋白的阳性率在正常子宫颈/慢性子宫颈炎组分别为5.6％(2/36)、2.8％(1/36)及0(0/36),在LSIL组分别为40.3％(31/77)、50.6％(39/77)及27.3％(21/77),在HSIL组分别为85.5％(59/69)、91.3％(63/69)及88.4％(61/69),HR-HPV感染率在三组中分别为25％(9/36)、63.6％(49/77)及92.8％(64/69),BAG-1、MCM2、p16阳性率及HR-HPV感染率均随SIL病变程度上升而增高(P均<0.05).不管在LSIL组还是HSIL组,BAG-1、MCM2表达与p16表达、HR-HPV感染均呈正相关(P均<0.05).结论 BAG-1及MCM2表达与SIL病变程度、p16表达及HR-HPV感染状态呈正相关,它们可能参与了子宫颈SIL的发生、发展过程.

目的:探讨微小RNA-126(miR-126)增强胃癌细胞放射敏感性的分子生物学机制.方法:体外培养胃癌SGC-7901细胞,通过转染miR-126模拟序列上调细胞内的miR-126水平,使用RT-qPCR及Western blot检测miR-126上调后zeste基因增强子同源物2(EZH2)的mRNA及蛋白水平的变化.双萤光素酶报告基因实验确认miR-126与EZH2的靶向结合关系.在上调miR-126水平的同时,通过共转染pcDNA3.1-EZH2真核表达质粒提高细胞内的EZH2表达,CCK-8法及流式细胞术分析照射后胃癌细胞的活力及凋亡率的变化,从而评估EZH2过表达对miR-126放射增敏作用的影响.结果:上调胃癌SGC-7901细胞中的miR-126水平可以显著抑制EZH2的mRNA及蛋白水平(P<0.05).双萤光素酶报告基因实验提示miR-126与EZH2的mRNA间存在直接靶向关系.与仅上调miR-126的细胞相比,上调miR-126水平的同时过表达EZH2水平,将导致照射后SGC-7901细胞的活力增加,凋亡率减少(P<0.05).结论:对EZH2靶向抑制是miR-126增强胃癌SGC-7901细胞放射敏感性的机制之一.

目的:探讨组织间插植在宫颈残端癌、阴道残端复发癌放疗中的近期疗效.方法:对35例诊断明确的宫颈残端癌、阴道残端复发癌行组织间插植放疗联合经典的体外照射及近距离腔内照射的模式,观察近期疗效及不良反应.结果:35例宫颈残端癌、阴道残端复发癌放疗结束评价疗效,达到完全缓解30例患者(85.7％),部分缓解5例患者(14.3％),治疗有效率可达100％.观察不良反应:35例患者均出现了不同程度的骨髓抑制,其中30例患者(85.7％)出现1～3级骨髓抑制,5例患者(14.3％)出现3～4级骨髓抑制.22例患者(62.9％)出现1～3级急性放射性直肠炎症状,15例患者(42.9％)出现1～3级急性放射性膀胱炎症状,但未出现3级以上的急性放射性副反应.结论:组织间插植对于宫颈残端癌、阴道残端复发癌是一种有效的治疗方式,可明显提高局部控制率高、完全缓解率、部分缓解率,且无严重的近期不良反应发生,具有很好的治疗可行性,相对安全可靠.

目的:探讨局部中晚期宫颈癌放射治疗前后的MRI表现,评价MRI在宫颈癌放疗前后的临床价值.方法:对122例局部中晚期宫颈癌分别进行放射治疗前后MRI检查,对肿瘤大小、信号,宫旁受侵、盆腔淋巴结等进行对比.结果:122例患者中,肿瘤明显缩小或消失106例,轻度缩小16例,肿瘤总体信号降低109例,信号不均匀13例,淋巴结缩小或消失48例.宫颈癌放射治疗前后与宫旁组织对比,观察内容均清晰.结论:MRI检查对宫颈癌放射治疗疗效及预后评价具有重要意义.

目的:探讨高能电子线治疗瘢痕瘤的疗效及其影响因素.方法:选取2000年至2014年间甘肃省肿瘤医院及甘肃省人民医院放疗科收治的可随访瘢痕瘤患者206例,均采用6MeV或9MeV电子线源皮距照射技术放射治疗,分析其临床疗效及影响因素.结果:206处瘢痕瘤患者电子线治疗有效率为90.3％,瘢痕长度、瘢痕面积、术后开始放疗时间、术后放疗方式、瘢痕部位与电子线疗效有关;多因素分析显示瘢痕部位、术后开始放疗时间为影响电子线疗效的因素.结论:高能电子线是治疗瘢痕瘤的有效手段,术后开始治疗时间,瘢痕治疗面平坦是该法治疗效果的重要影响因素.

目的:分析局部晚期直肠癌单药卡培他滨与XELOX方案术前新辅助同步放化疗的疗效及不良反应.方法:对2008年至2012年经病理诊断Ⅱ-Ⅲ期直肠腺癌患者进行研究,共计60例.A组术前采用单药卡培他滨同步放化疗治疗,B组采用双药奥沙利铂联合卡培他滨同步放化疗治疗,比较两组治疗效果.结果:A组术后有16例患者降期,B组18例降低分期;经新辅助治疗后病理学检测显示,A组pCR率为26.7%,B组30%;随访20个月,两组OS率分别为91.2%,92.4%,DFS率分别为69.5%和63.3%;以上差异均无统计学差异(P>0.05).A组腹泻11例低于B组18例;A组胃肠道反应10例低于B组22例;A组血液学毒性6例低于B组15例,以上差异均具有统计学意义(P<0.05).结论:局部晚期直肠癌同步放化疗单药卡培他滨化疗疗效良好.

AIM: To investigate the influences of microRNA-126 on the curative effect of chemoradiotherapy and radiosensitivity of SGC-7901 cells.METHODS: The patients of gastric cancer (n=60) were selected in this study including 32 males and 28 females with the average age of (51±7) years.All patients received similar chemoradiotherapy strategy.The tissue and blood samples were collected during treatment.The short-term curative effect was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST), and the patients were divided into sensitive group and insensitive group.The microRNA-126 levels were detected by RT-qPCR.The SGC-7901 cells were maintained in vitro and transfected with microRNA-126 mimic.The plate colony formation assay was used to determine the enhancement effect of microRNA-126 on radiosensitivity of the SGC-7901 cells.The apoptotic rate of the SGC-7901 cells induced by microRNA-126 was analyzed by flow cytometry.RESULTS: According to the RECIST, 28 cases were defined as sensitive patients and 32 cases were the insensitive patients.Compared with the sensitive patients, the microRNA-126 levels both in blood and tissue samples were lowered in the insensitive patients, and the relative fold changes were 0.72±0.04 and 0.48±0.03, respectively (P<0.05).After transfection with microRNA-126 minic, the SF2 and D0 in the SGC-7901 cells were decreased with the SER of 1.74.Furthermore, microRNA-126 induced apoptosis of SGC-7901 cells and enhanced their radiosensitivity.CONCLUSION: The patients with low microRNA-126 level may suffer a poor curative effect of chemoradiotherapy on the gastric cancer.MicroRNA-126 has an enhancement effect on the radiosensitivity to the SGC-7901 cells.

目的：研究不同化疗方案并同步放疗治疗中晚期宫颈癌的临床疗效。方法：将2006年1月至2008年12月收治的135例中晚期宫颈癌患者分为3组进行治疗，A组为单纯放疗组（45例）、B组为顺铂联合放疗组（45例）和C组为顺铂和紫杉醇联合放疗组（45例），治疗及随访期间比较三组近期疗效、5年生存率及不良反应。结果：A、B、C三组近期有效率分别为75.6%，91.1%和93.3%， A组与B组、A组与C组间相比，差异有统计学意义（P＜0.05），而B组与C组间相比，差异无统计学意义（P＞0.05）。 A、B、C三组5年生存率分别为33.3％，55.6％和75.6％，三组间相比差异有统计学意义（P＜0.05）。三组放射性直肠炎及放射性膀胱炎发生率差异无统计学意义（P＞0.05），但恶心、呕吐等消化道反应及白细胞降低等骨髓抑制发生率在B组与C组较A组增高，A组与B组、A组与C组间相比，差异有统计学意义（P＜0.05），而B组与C组间相比，差异无统计学意义（P＞0.05），上述不良反应经积极处理后均能够耐受。结论：顺铂和紫杉醇化疗方案联合放疗可提高中晚期宫颈癌的近期疗效及5年生存率,不良反应少,可作为中晚期宫颈癌同步放、化疗最佳方案的选择。

目的 探讨放射联合唑来膦酸治疗骨转移瘤的方法及临床疗效.方法 将181例骨转移瘤患者随机分为3组,放射治疗联合唑来膦酸治疗组(A组)86例,单纯放射治疗组(B组)58例,单纯唑来膦酸治疗组(C组)37例,比较各组止痛及改善活动能力的效果.结果 治疗结束后1周时,A组、B组和C组止痛有效率分别为82.6％、70.7％和59.5％,A组与C组有效率差异有统计学意义(P＜0.05),但A组与B组总有效率差异无统计学意义;A组对活动能力改善总有效率与B组、C组比较,差异无统计学意义.随访2月后A组、B组及C组止痛有效率分别为87.2％、70.7％和67.6％,A组缓解骨转移瘤疼痛较B组及C组明显(P＜0.05);A组对活动能力改善总有效率与B组及C组比较,差异有统计学意义(P＜0.05).结论 放射联合唑来膦酸治疗骨转移瘤疗效优于单纯放射治疗或单纯唑来膦酸治疗,可明显提高患者疼痛缓解率,延长疼痛缓解时间,显著改善患者活动能力,是治疗骨转移瘤的理想方案.